Renan Pereira de Lima

Renan Pereira de Lima

Auto-generated profile, based on publicly available information

Renan Pereira de Lima

Universidade Federal do Ceará, Brasil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
RLR.P. de Lima
R.P. de Lima
PNPaulo Iury Gomes Nunes
Paulo Iury Gomes Nunes
AVA.F.S.C. Viana
A.F.S.C. Viana
FOF.T.B. de Oliveira
F.T.B. de Oliveira
RSR.A.C. Silva
R.A.C. Silva
FSFlavia A Santos
Flavia A Santos
Nonalcoholic fatty liver disease (NAFLD), characterized by hepatosteatosis and steatohepatitis, is intrinsically related to obesity. Our previous study reported on the anti-obese activity of α,β-amyrin (AMY), a pentacyclic triterpene isolated from Protium heptaphyllum. This study investigated its ability to prevent fatty liver and the underlying mechanism using the mouse model of NAFLD. NAFLD was induced in male Swiss mice fed a high fat diet (HFD) for 15 weeks. The controls were fed a normal chow diet (ND). The mice were simultaneously treated with AMY at 10 and 20 mg/kg or fenofibrate at 50 mg/kg. Lipid levels along with metabolic and inflammatory parameters were assessed in liver and serum. The liver sections were histologically examined using H&E staining. RT-qPCR and western blotting assays were performed to analyze signaling mechanisms. Mice fed HFD developed severe hepatic steatosis with elevated triglycerides and lipid droplets compared with ND controls. This was associated with a decrease in AMP-activated protein kinase (AMPK) activity, an increase of mechanistic target of rapamycin complex 1 (mTORC1) signaling, and enhanced sterol regulatory element binding protein 1 (SREBP1) expression, which have roles in lipogenesis, inhibition of lipolysis, and inflammatory response. AMY treatment reversed these signaling activities and decreased the severity of hepatic steatosis and inflammatory response, evidenced by serum and liver parameters as well as histological findings. AMY-induced reduction in hepatic steatosis seemed to involve AMPK-mTORC1-SREBP1 signaling pathways, which supported its beneficial role in the prevention and treatment of NAFLD.

1 January 2018 in Bioactive Carbohydrates and Dietary Fibre
Verified
Journal Article
Open access
DCDiana Valesca Carvalho
Diana Valesca Carvalho
FSFlavia A Santos
Flavia A Santos
RLRenan Pereira de Lima
Renan Pereira de Lima
AVAna Flávia Seraine Custódio Viana
Ana Flávia Seraine Custódio Viana
SFSaid Gonçalves Cruz Fonseca
Said Gonçalves Cruz Fonseca
EBEdy Sousa de Brito
Edy Sousa de Brito

1 January 2025 in Brazilian Journal of Biology
Verified
Journal Article
Open access
PDF file
ASA. V. L. Silva
A. V. L. Silva
RLR. P. Lima
R. P. Lima
FOF. T. B. Oliveira
F. T. B. Oliveira
AQA. L. G. Quinderé
A. L. G. Quinderé
NBNorma M. B. Benevides
Norma M. B. Benevides
FSFlavia A Santos
Flavia A Santos
Obesity is a global public health issue, closely linked to cardiovascular disease and type 2 diabetes. Pharmacological interventions for weight loss are one option for treating obesity; however, these drugs often come with side effects or limited efficacy, highlighting the need for new therapies. Marine algae offer a promising source of biologically active compounds for human health, including antidiabetic, anti-inflammatory, and anti-obesity properties. Sulfated galactan isolated from the red marine algae Acanthophora muscoides (SGAM) has demonstrated diverse biological activities including anti-inflammatory activity in vivo and in vitro studies. However, its potential impact on adipogenesis remains unexplored. This study evaluated the effect of SGAM on adipogenesis in 3T3-L1 cells using Oil Red O staining and analyzed the protein expression of key transcription factors associated with adipogenesis. SGAM (25−100 μg/mL) was found to reduce intracellular lipid accumulation in adipocytes without compromising cell viability. Furthermore, our findings suggest that SGAM significantly inhibits adipocyte differentiation by downregulating the expression of key adipogenesis-related transcription factors, including C/EBPβ, C/EBPδ, C/EBPα, and PPARγ. Additionally, SGAM reduced the protein expression of SREBP-1 and promoted the activation of AMPK. In conclusion, SGAM inhibits adipogenesis by negatively modulating the expression of the main adipogenic transcription factors and activating AMPK.

1 August 2024 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
GFGabrielle de Paula Freire
Gabrielle de Paula Freire
LFLuiz Carlos Pereira Almeida Filho
Luiz Carlos Pereira Almeida Filho
PRPaulo Ribeiro
Paulo Ribeiro
PNPaulo Iury Gomes Nunes
Paulo Iury Gomes Nunes
RLRenan Pereira de Lima
Renan Pereira de Lima
FSFlavia A Santos
Flavia A Santos

26 February 2026 in ACS Omega
Verified
Journal Article
Open access
RLRenan P. de Lima
Renan P. de Lima
FOFrancisca Tuelly B. de Oliveira
Francisca Tuelly B. de Oliveira
ASAna Virginia L. da Silva
Ana Virginia L. da Silva
MAMaria Rose Jane R. Albuquerque
Maria Rose Jane R. Albuquerque
OPOtília D. L. Pessoa
Otília D. L. Pessoa
FSFlavia A Santos
Flavia A Santos
Insulin resistance, obesity, and type 2 diabetes mellitus (T2DM) are interrelated metabolic disorders with rising global prevalence. Triterpenes, known for their diverse pharmacological properties, have shown potential in improving insulin sensitivity and exerting antidiabetic and antiobesity effects. This study evaluated the effects of taraxasterol acetate (TXA), a pentacyclic triterpene isolated from Eupatorium ballotaefolium, on TNF-α-induced insulin resistance and lipolysis in mature 3T3-L1 adipocytes. TXA significantly enhanced glucose uptake in insulin-resistant adipocytes by promoting GLUT4 translocation by activating the IRS-1/PI3K/Akt signaling pathway and upregulating AMPK expression. TXA also inhibited NF-κB and JNK signaling, reducing inflammation and mitigated oxidative stress by decreasing intracellular reactive oxygen species (ROS) levels and enhancing antioxidant enzyme activity, including superoxide dismutase (SOD) and catalase (CAT). Moreover, TXA normalized adipokine secretion by increasing leptin and adiponectin levels, and promoted lipid accumulation through the modulation of PPARγ, HSL, ATGL, and Perilipin expression. TXA further improved lipid metabolism by upregulating fatty acid β-oxidation genes (ACOX1, CPT1b) and supported mitochondrial function by enhancing PGC-1α and TFAM expression. Collectively, these findings demonstrate that TXA mitigates TNF-α-induced insulin resistance by improving insulin signaling, suppressing inflammation and oxidative stress, and improving lipid and mitochondrial metabolism. These results suggest that TXA is a promising therapeutic candidate for the prevention and treatment of insulin resistance and related metabolic disorders.

3 April 2024 in Infarma - Ciências Farmacêuticas
Verified
Journal Article
Open access
PDF file
LSLuenil Zairone de Freitas Schuring
Luenil Zairone de Freitas Schuring
MSMarciana Alves Da Silva
Marciana Alves Da Silva
RBRafaela de Sousa Brito
Rafaela de Sousa Brito
VEVinícius Araújo Estevão
Vinícius Araújo Estevão
RLRenan Pereira De Lima
Renan Pereira De Lima
PNPaulo Iury Gomes Nunes
Paulo Iury Gomes Nunes
A Farmácia Clínica (FC) abrange as práticas farmacêuticas voltadas para a otimização da farmacoterapia, buscando melhores resultados clínicos, minimizando os riscos e custos envolvidos em sua utilização, além de estimular a prática do uso racional de medicamentos. Assim, este trabalhoteve como finalidade avaliar a influência e evolução nacional dos estudos acadêmicos sobre FC, traçando o cenário nacional sobre o tema entre os anos de 2001 e 2021, utilizando como ferramentas de busca e coleta de dados o Portal Brasileiro de Publicações Científicas em Acesso Aberto (Ibict--Oasisbr) e a Plataforma Lattes gerenciada pelo Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Ao todo, 117 produções acadêmicas foram encontradas tendo como assunto de suas investigações a FC e tais produções dividiram-se entre 38 instituições distribuídas por todoo território nacional. A Região Sul foi responsável por 28,20% das produções no período analisado, sendo seguida pelas Regiões Sudeste com 26,50%, Nordeste com 18,8%, Centro-Oeste com 8,55% e Norte com 5,98%, fato condizente com o atual cenário de distribuição de pesquisadores e grupos depesquisa no país e com a histórica diferença socioeconômica entre as diferentes regiões do Brasil. Diante do exposto, foi possível concluir que a temática FC vem sendo trabalhada à margem de outros temas norteadores de pesquisa na área da saúde, como a Atenção Farmacêutica, a Assistência Farmacêutica e a Farmácia Hospitalar. Além disso, foi observada uma desigualdade quanto ao número de estudos realizados nas diferentes regiões do país, sendo necessárias investigações posteriores e de maior abrangência para o melhor entendimento e caracterização desses achados.